الإحصائيات الأساسية
| LEI | 549300WZMFR0ZK7RJY40 |
| CIK | 1541884 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pulmonx Corporation
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 22, 2024 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Com |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 1, 2023 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-38362 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 202 |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exact na |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-38362 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 20 |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 001-38362 (Commission File No.) PROLUNG, INC. (Exact name of |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-38362 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG,INC. (Exact |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exact nam |
|
| June 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2022 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exact na |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ? Definitive Proxy Stat |
|
| May 4, 2022 |
PART I — REGISTRANT INFORMATION NT 10-Q 1 formnt10-q.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-38362 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Fo |
|
| May 3, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2 |
|
| May 3, 2022 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 001-38362 (Commission File No.) PROLUNG, INC. (Exact name of |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-K 1 formnt10k.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-38362 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Pe |
|
| March 8, 2022 |
IONIQ Sciences Announces Acquisition of Intellectual Property and Buyout of License Exhibit 99.1 IONIQ Sciences Announces Acquisition of Intellectual Property and Buyout of License Salt Lake City, UT, March 8, 2022 ? ProLung, Inc. dba IONIQ Sciences, Inc. (?IONIQ? or the ?Company?) announced today that it has acquired from OT Acceptance, LLC (?OT Acceptance?) certain intellectual property formerly licensed to the Company by OT Acceptance. With this acquisition, the Company now ow |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2022 ProLung Inc (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporation |
|
| February 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 2, 2022 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| February 3, 2022 |
IONIQ Sciences Announces Submission of De Novo Application to FDA Exhibit 99.1 IONIQ Sciences Announces Submission of De Novo Application to FDA Salt Lake City, UT, February 2, 2022 ? ProLung Inc., doing business as IONIQ Sciences, (?IONIQ? or the ?Company?) announced today that it has filed a De Novo application with the U.S. Food and Drug Administration (the ?FDA?) for its IONIQ ProLung Test? used for lung cancer. Mr. Jared Bauer, IONIQ Sciences CEO, stated, ? |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exac |
|
| October 7, 2021 |
IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Exhibit 99.1 IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 ? IONIQ Sciences, Inc. (?IONIQ? or the ?Company?), is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today ION |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 7, 2021 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporat |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exact nam |
|
| July 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2021 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| May 28, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 28, 2021 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporation |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ???????????????????????? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 001-38362 (Commission File No.) PROLUNG, INC. (Exact name |
|
| May 3, 2021 |
Exhibit 3.1 |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. ( |
|
| September 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exact |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-38362 PROLUNG, INC. (Exac |
|
| July 15, 2020 |
Exhibit 10.13 |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 001-38362 (Commission File No.) PROLUNG, INC. (Exact name |
|
| July 15, 2020 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK As of the date of this prospectus, our authorized capital stock consists of 120,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. A description of material terms and provisions of our amended and restated certificate of incorporation and amended and restated bylaws affecting the rights of holders o |
|
| July 15, 2020 |
Exhibit 3.1 |
|
| May 28, 2020 |
IONIQ Sciences announces institutional offering Exhibit 99.2 IONIQ Sciences announces institutional offering Salt Lake City, UT, May 28, 2020 – IONIQ Sciences Inc. (“IONIQ Sciences” or the “Company”), announced it is initiating an institutional private equity offering on the heels of receiving ‘Breakthrough Device Designation’ from the U.S. FDA for its lung cancer test. IONIQ Sciences has also re-branded from ProLung, Inc. to IONIQ Sciences, In |
|
| May 28, 2020 |
Exhibit 99.1 ProLung announces corporate name change to IONIQ Sciences to reflect expanded early cancer detection strategy Salt Lake City, UT, May 27, 2020 – IONIQ Sciences Inc. (“IONIQ Sciences” or the “Company”), which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics (EIA) technology and a proprietary algorithm |
|
| May 28, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 27, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporation |
|
| May 22, 2020 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 22, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporation |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-38362 PROLUNG, INC. ( |
|
| March 10, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 9, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Emp |
|
| March 10, 2020 | ||
| March 4, 2020 |
LUNG / ProLung, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (Exact |
|
| February 27, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 13, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 12, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| February 13, 2020 |
ProLung Test™ Granted ‘Breakthrough Device’ Designation by the FDA Exhibit 99.1 ProLung Test™ Granted ‘Breakthrough Device’ Designation by the FDA Salt Lake City, UT, February 13, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has developed a cutting edge predictive analytic that utilizes bioconductance to reduce the time to cancer diagnosis, announced that its ProLung Test™ has been designated a ‘Breakthrough Device’ by the U.S. Food and Drug Administr |
|
| February 13, 2020 |
Order of Dismissal of the Utah Division of Securities dated January 15, 2020, exhibit 99.3 Exhibit 99.3 |
|
| February 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 13, 2020 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| February 13, 2020 |
Stipulation and Consent Order of the Utah Division of Securities dated January 9, 2020, exhibit 99.2 Exhibit 99.2 |
|
| February 13, 2020 |
ProLung Announces End of 2012-2014 Governance Issues Exhibit 99.1 ProLung Announces End of 2012-2014 Governance Issues Salt Lake City, UT, February 12, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has developed a cutting edge predictive cancer analytic that utilizes bioconductance to reduce the time to diagnosis, announced that the Utah Division of Securities (“Division”) has dismissed all charges of securities fraud against ProLung and |
|
| January 13, 2020 |
LUNG / ProLung, Inc. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| December 31, 2019 |
LUNG / ProLung, Inc. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| December 31, 2019 |
LUNG / ProLung, Inc. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| December 31, 2019 |
LUNG / ProLung, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| November 27, 2019 |
Exhibit 99.4 |
|
| November 27, 2019 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 27, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| November 27, 2019 |
Exhibit 99.2 |
|
| November 27, 2019 |
Exhibit 99.3 |
|
| November 27, 2019 |
Exhibit 99.1 |
|
| November 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 26, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| November 26, 2019 |
ProLung Announces Change to its Board of Directors ProLung Announces Change to its Board of Directors Salt Lake City, UT, November 26, 2019 – ProLung, Inc. |
|
| October 3, 2019 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity Salt Lake City, UT, October 3, 2019 – ProLung, Inc. (“ProLung” or the “Company”) and its long-time partner ProLung China (a Delaware, USA-based company), both whom are focused on reducing the time to diagnosis for lung cancer patients, proudly announced today t |
|
| October 3, 2019 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporati |
|
| August 12, 2019 |
LUNG / ProLung, Inc. NT 10-Q - - OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-54600 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended |
|
| August 12, 2019 |
ProLung Announces the Appointment of Leavitt Partners and Mr. Rich ProLung Announces the Appointment of Leavitt Partners and Mr. Rich August 12, 2019 SALT LAKE CITY, UT / ACCESSWIRE / August 12, 2019 / ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced today the appointment of Leavitt Partners to the ProLung Board of Directors with Mr. Rich McKeown acting as its designee. The appointm |
|
| August 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporati |
|
| August 2, 2019 | ||
| August 2, 2019 | ||
| August 2, 2019 | ||
| August 2, 2019 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 2, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporati |
|
| August 2, 2019 | ||
| June 20, 2019 |
LUNG / ProLung, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (Exac |
|
| June 12, 2019 |
Dear ProLung Shareholders and Friends, Dear ProLung Shareholders and Friends, ProLung is delighted to announce exciting Board and Leadership changes along with plans for new office and lab space, which are designed to further sharpen our focus on achieving FDA clearance and commercial success. |
|
| June 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2019 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporatio |
|
| June 12, 2019 |
EX-99.1 2 ex99-1.htm PRESS RELEASE FOR IMMEDIATE RELEASE ProLung Announces Changes to its Board of Directors and Leadership Team to Enhance its Medtech Expertise Salt Lake City, UT, June 12, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced the appointments of Messers. Jim Hogan, David Nielsen and Don Patterson |
|
| May 15, 2019 |
NT 10-Q 1 formnt10-q.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-54600 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Fo |
|
| April 16, 2019 |
Exhibit 21.1 List of Subsidiaries Hilltop Acquisition Corporation, Inc., a Delaware corporation (100% owned) |
|
| April 16, 2019 |
LUNG / ProLung, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, INC. (Exact name |
|
| April 1, 2019 |
NT 10-K 1 formnt10-k.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-54600 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Fo |
|
| December 11, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 3, 2018 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 26, 2018 |
LUNG / ProLung, Inc. ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate Box: ☐ Preliminary Proxy Statement ☐ Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statem |
|
| November 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| November 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| November 14, 2018 |
LUNG / ProLung, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. ( |
|
| November 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| November 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| November 6, 2018 |
Amendment No. 1 to the Bylaws of ProLung, Inc., dated November 1, 2018. AMENDMENT NO. 1 TO BYLAWS OF PROLUNG, INC. This Amendment No. 1 to the First Amended and Restated Bylaws (the “Bylaws”) of ProLung, Inc., a Delaware corporation (the “Company”), is dated as of November 1, 2018 (this “Amendment No. 1”). Recitals WHEREAS, the Board of Directors of the Corporation (the “Board”) has approved Amendment No. 1 as set forth below, in accordance with Article 8, Section 6 o |
|
| November 6, 2018 |
PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION—DATED NOVEMBER 5, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 25, 2018 |
Submission of Matters to a Vote of Security Holders, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 25, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| October 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| October 23, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung Announces Preliminary Results of Consent Solicitation Consent Solicitation Clearly Failed to Receive the Required Majority Steven Eror Falsely Claimed Victory for the Third Time Salt Lake City, UT, October 23, 2018 – ProLung, Inc. |
|
| October 23, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung Announces Preliminary Results of Consent Solicitation Consent Solicitation Clearly Failed to Receive the Required Majority Steven Eror Falsely Claimed Victory for the Third Time Salt Lake City, UT, October 23, 2018 – ProLung, Inc. |
|
| October 23, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 23, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 16, 2018 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax AMERICA ● ASIA PACIFIC ● EUROPE October 16, 2018 Via EDGAR, Email and FedEx Nicholas P. |
|
| October 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| October 2, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE FORMER PROLUNG DIRECTORS SUPPORT THE COMPANY’S INTERIM CEO JARED BAUER AND INCUMBENT BOARD OF DIRECTORS Salt Lake City, UT, October 2, 2018 – ProLung, Inc. |
|
| October 2, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| October 1, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung Advises Shareholders to Disregard Former CEO’s Steven Eror’s Recent Illegal Press Release Board In Fact Leads Substantially in the Vote Tally ProLung Urges Shareholders to Continue to Sign and Submit the GOLD Card Salt Lake City, UT, October 1, 2018 – The board of directors (the “Board”) of ProLung, Inc. |
|
| October 1, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 1, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| September 19, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 19, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (C |
|
| September 19, 2018 |
EX-99.1 2 ex99-1.htm PRESS RELEASE FOR IMMEDIATE RELEASE ProLung, Inc. Announces Addition of Future Board Members Additions bring extensive operating experience in medical technology and diagnostics as well as repeated success with the FDA approval process Salt Lake City, UT, September 19, 2018 – ProLung, Inc. (“ProLung” or the “Company”) today announced the appointment of Rob Farnsworth and David |
|
| September 13, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 13, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of incorporation or organization) (C |
|
| September 13, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung, Inc. Announces Organizational Changes to Sharpen Focus on Achieving FDA Approval and Successful Commercialization Jared Bauer Named Interim CEO and Details Seven-Point Go-Forward Strategy Salt Lake City, UT, September 13, 2018 – ProLung, Inc. (“ProLung” or the “Company”) today announced the Company is taking significant steps to better align its product |
|
| September 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| September 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| August 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate Box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Pr |
|
| August 27, 2018 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 27, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38362 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporat |
|
| August 27, 2018 |
EX-99.1 2 ex99-1.htm PRESS RELEASE FOR IMMEDIATE RELEASE ProLung, Inc. Releases Communication Urging Stockholders Not to Respond to Consent Solicitation by Steven C. Eror Salt Lake City, UT, August 27, 2018 – ProLung, Inc. (“ProLung” or the “Company”) today released a communication urging stockholders to fill out and return the GOLD consent revocation card from the Company, which they can use to d |
|
| August 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| August 27, 2018 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax Kai Haakon E. |
|
| August 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 24, 2018 |
Sidley Austin LLP 787 Seventh Avenue New York, NY 10019 +1 212 839 5300 +1 212 839 5599 Fax Kai Haakon E. |
|
| August 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ C |
|
| August 22, 2018 |
O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212. |
|
| August 21, 2018 |
LUNG / ProLung, Inc. / EROR STEVEN C - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 ProLung, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74348P209 (CUSIP Number) steven c. eror PO Box 9 |
|
| August 21, 2018 |
O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212. |
|
| August 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ |
|
| August 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| August 16, 2018 |
O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212. |
|
| August 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ |
|
| August 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 15, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 15, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporat |
|
| August 15, 2018 |
PRESS RELEASE FOR IMMEDIATE RELEASE ProLung, Inc. Releases Communication Urging Stockholders Not to Respond to Consent Solicitation by Steven C. Eror Salt Lake City, UT, August 15, 2018 – ProLung, Inc. (“ProLung” or the “Company”) today released a communication urging stockholders not to respond to the consent solicitation by Steven C. Eror. The Company announced that stockholders will soon receiv |
|
| August 15, 2018 |
Security Ownership of Directors and Officers Security Ownership of Directors and Officers The following table lists, as of August 13, 2018, the number of shares of common stock of ProLung, Inc. |
|
| August 14, 2018 |
LUNG / ProLung, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (Exact |
|
| August 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ C |
|
| August 7, 2018 |
LUNG / ProLung, Inc. / EROR STEVEN C - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 ProLung, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74348P209 (CUSIP Number) steven c. eror PO Box 9 |
|
| August 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| August 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporatio |
|
| July 31, 2018 |
Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Steven C. Eror the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of ProLung, Inc. (the “Company”) directly or indirectly beneficially owne |
|
| July 31, 2018 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, ProLung, Inc., a Delaware corporation (the “Company”); WHEREAS, Steven C. Eror, Richard Serbin, Michael N. Christiansen, Todd M. Morgan, Eric M. Sokol, Ron Dunford, Brian W. Loveridge and Don A. Patterson wish to form a group for the purpose of (i) seeking representation |
|
| July 31, 2018 |
STEVEN C. EROR PO Box 981194 Park City, Utah 84098 Exhibit 99.3 STEVEN C. EROR PO Box 981194 Park City, Utah 84098 July 26, 2018 VIA E-MAIL, FACSIMILE AND OVERNIGHT DELIVERY ProLung, Inc. 757 East South Temple, Suite 150 Salt Lake City, UT 84012 Attn: Mark V. Anderson, Chief Financial Officer and Corporate Secretary Re: Shareholder Request To Set A Record Date For Determining Shareholders Entitled To Express Consent To Corporate Action In Writing |
|
| July 31, 2018 |
LUNG / ProLung, Inc. / EROR STEVEN C - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 ProLung, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74348P209 (CUSIP Number) steven c. eror PO Box 9 |
|
| July 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 10, 2018 |
ProLung, Inc. Frequently Asked Questions July 10, 2018 ProLung, Inc. Frequently Asked Questions July 10, 2018 We have announced via Form 8-K the termination of the employment of Steven C. Eror, our former Chief Executive Officer, the resignation of certain directors and the appointment of a new interim Chief Executive Officer and two directors. We understand that stockholders are concerned about what these changes mean for the future of ProLung. Set f |
|
| July 10, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2018 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporatio |
|
| June 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 26, 2018 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorporatio |
|
| May 21, 2018 |
LUNG / ProLung, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (Exac |
|
| May 21, 2018 |
Offer Letter with Neil Berkley* EXHIBIT 10.3 February 22, 2018 Neil Berkley 5829 Gablewood Way San Diego, CA 92130 Via Email to: [email protected] RE: ProLung, Inc., BOARD OF DIRECTORS (“Board”) Dear Neil, On behalf of the Management and the Board of ProLung, Inc. (“Company”), effective 22 February 2018, I extend this offer to you to serve as a Director and member of the Board of Directors of the Company. Both the Compan |
|
| May 21, 2018 |
Form of Warrant issuable to Placement Agent* EXHIBIT 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE OFFERED, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AND SUCH REGISTRATION OR QUALIFICATION AS MAY BE NECESSAR |
|
| May 16, 2018 |
NT 10-Q 1 nt10-q.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-54600 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N |
|
| April 17, 2018 |
Form of 8% Convertible Promissory Note issued beginning March 1, 2018* US$ Note No. Issue Date: Maturity Date: PROLUNG, INC. EIGHT PERCENT (8%) CONVERTIBLE NOTE THIS NOTE, AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED OR SOLD IN THE ABSEN |
|
| April 17, 2018 |
Placement Agent Agreement dated February 27, 2018 with Weild Capital(2) CONFIDENTIAL February 27, 2018 Weild & Co. 777 29th Street Suite 402 Boulder, CO 80303 USA Attention: David Weild IV, CEO Dear David: This letter agreement (this “Agreement”) confirms our understanding with respect to our engagement of Weild & Co., Inc., a Delaware corporation, through its subsidiary broker/dealer Weild Capital, LLC (collectively, the “Agent”) to serve as exclusive “Placement Agen |
|
| April 17, 2018 |
Exhibit 21.1 List of Subsidiaries Hilltop Acquisition Corporation, Inc., a Delaware corporation (100% owned) |
|
| April 17, 2018 | ||
| April 17, 2018 |
LUNG / ProLung, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, INC. (Exact name |
|
| April 17, 2018 |
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROLUNG, INC. ProLung, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on November 19, 2004. The orig |
|
| April 2, 2018 |
NT 10-K 1 formnt10-k.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-54600 CUSIP NUMBER NOTIFICATION OF LATE FILING 74348P209 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Fo |
|
| February 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2018 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 28, 2018 |
ProLung, Inc. Announces Appointment of Neil Berkley to its Board of Directors ProLung, Inc. Announces Appointment of Neil Berkley to its Board of Directors Salt Lake City, UT, February 27, 2018, ? ProLung, Inc., (?ProLung? or the ?Company?) the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today that Neil Berkley has joined the Company?s Board of Directors. Steven C. Eror, President an |
|
| February 14, 2018 |
As filed with the Securities and Exchange Commission on February 14 , 2018 Registration No. |
|
| January 25, 2018 |
As filed with the Securities and Exchange Commission on January 2 5 , 2018 Registration No. |
|
| January 24, 2018 |
As filed with the Securities and Exchange Commission on January 24, 2018 Registration No. |
|
| January 23, 2018 |
Form of Underwriters’ Warrant.(14) Form of Underwriter?s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE LATER OF THE EFFECTIVE DATE (AS DEFINED BELOW) OR THE COMMENCEMENT OF SALES OF THE OFFERING TO WHICH THIS PURCHASE WARRANT RELATES TO ANYONE OTHER THAN (I) MAXIM GROUP LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF MAXIM GROUP LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER. |
|
| January 23, 2018 |
As filed with the Securities and Exchange Commission on January 22, 2018 Registration No. |
|
| January 23, 2018 |
Form of Underwriting Agreement.(14) EXHIBIT 1.1 PROLUNG, INC. UNDERWRITING AGREEMENT January [?], 2018 MAXIM GROUP LLC 405 Lexington Avenue New York, NY 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, ProLung, Inc., a Delaware corporation (the ?Company?), hereby confirms its agreement (this ?Agreement?) to issue and sell to the several underwriters named on Schedule A att |
|
| January 23, 2018 |
8-A12B 1 form8a12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROLUNG, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 20-1922768 (I.R.S. Employer Ide |
|
| January 16, 2018 |
As filed with the Securities and Exchange Commission on January 16, 2018 Registration No. |
|
| January 4, 2018 |
LUNG / ProLung, Inc. / Raybould Robert W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ProLung, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 35804P 108 (CUSIP Number) Robert Raybould 757 E. South Temple, Suite 150 Salt Lake City, Utah 84102 (Name, Address and Telephone Number of Person Authorized to R |
|
| December 21, 2017 |
As filed with the Securities and Exchange Commission on December 21 , 2017 Registration No. |
|
| November 29, 2017 |
Consulting Agreement with Leavitt Partners dated July 1, 2014(10) Exhibit 10.1.3 Consulting Services Agreement We are pleased to confirm our mutual understanding in this Consulting Services Agreement (this ?Agreement?) between Leavitt Partners, LLC, a Utah limited liability company (the ?Company?), and Fresh Medical Laboratories, Inc. (?Client?), a Delaware Corporation, the ?Parties,? as follows: 1. Services. The Company shall provide the services (the ?Services |
|
| November 29, 2017 |
As filed with the Securities and Exchange Commission on November 28 , 2017 Registration No. |
|
| November 14, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2017 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| November 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. ( |
|
| October 30, 2017 | ||
| October 17, 2017 |
Exhibit 10.1.3 Consulting Services Agreement We are pleased to confirm our mutual understanding in this Consulting Services Agreement (this ?Agreement?) between Leavitt Partners, LLC, a Utah limited liability company (the ?Company?), and Fresh Medical Laboratories, Inc. (?Client?), a Delaware Corporation, the ?Parties,? as follows: 1. Services. The Company shall provide the services (the ?Services |
|
| October 17, 2017 |
As filed with the Securities and Exchange Commission on October 17, 2017 Registration No. |
|
| October 13, 2017 |
Certificate of Amendment effecting Reverse Stock Split CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF PROLUNG, INC. The undersigned officer of ProLung, Inc., formerly known as ProLung, Inc. (the ?Company?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: FIRST: That stockholders of the Company representing a majority of the voting power of |
|
| October 13, 2017 |
EXHIBIT 21.1 Subsidiary of ProLung, Inc. as of December 31, 2016 Hilltop Acquisition Corporation, Inc. |
|
| October 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, |
|
| October 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 10, 2017 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| October 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| September 22, 2017 |
PROLUNG SCIENCE AND TECHNOLOGY COMMITTEE CHARTER PROLUNG SCIENCE AND TECHNOLOGY COMMITTEE CHARTER I. Purpose The purpose of the Science and Technology Committee (the ?Committee?) of ProLung, Inc. (the ?Company?) is to assist the Board of Directors (the ?Board?) in ensuring that the research and development (?R&D?) carried out or supported by the Company is optimized to support the strategic goals of the Company and to provide recommendations to |
|
| September 22, 2017 | ||
| September 22, 2017 |
? |
|
| September 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| September 22, 2017 | ||
| September 15, 2017 |
EXHIBIT 21.1 Subsidiary of ProLung, Inc. as of December 31, 2016 Hilltop Acquisition Corporation, Inc. |
|
| September 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, |
|
| August 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (Exact |
|
| August 4, 2017 |
Consulting Services Agreement We are pleased to confirm our mutual understanding in this Consulting Services Agreement (this ?Agreement?) between Leavitt Partners, LLC, a Utah limited liability company (the ?Company?), and Fresh Medical Laboratories, Inc. |
|
| August 4, 2017 |
As filed with the Securities and Exchange Commission on ___________, 2017 As filed with the Securities and Exchange Commission on , 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROLUNG, INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) 757 East South Temple, Suite 150 Salt Lake City |
|
| July 21, 2017 |
PROLUNG, INC. STOCK INCENTIVE PLAN PROLUNG, INC. STOCK INCENTIVE PLAN 1. Purpose. The purpose of this Stock Incentive Plan (the ?Plan?) is to enable ProLung, Inc. (the ?Company?) to attract and retain the services of (i) selected employees, officers and directors of the Company or any parent or subsidiary of the Company and (ii) selected nonemployee agents, consultants, advisers and independent contractors of the Company or any par |
|
| July 21, 2017 |
As filed with the Securities and Exchange Commission on July 19, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2017 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 19, 2017 |
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROLUNG, INC. ProLung, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on November 19, 2004. 2. This |
|
| July 19, 2017 |
Amended and Restated By-Laws(1) FIRST AMENDED AND RESTATED BYLAWS OF PROLUNG, INC. (Adopted July 14, 2017) ARTICLE 1. STOCKHOLDERS 1.1 Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date, time and place, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time. Any other proper business may be transacted |
|
| June 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 23, 2017 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2017 Prolung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X . Filed by a Party other than the Registrant . Check the appropriate box: . Preliminary Proxy Statement . Confidential, for Use of the Commission Only (as Rule 14a-6(e)(2))permitted by Rule 14a-6(e)(2)) . Def |
|
| May 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment No. 1 X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLU |
|
| May 22, 2017 |
Consulting Agreement dated February 1, 2017 with Robin Smith(12) EXHIBIT 10.3 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT ("Agreement") is made and entered into effective as of February 1st, 2017, (the "Effective Date'') by and between Robin Smith MD MBA (the "Consultants"), and Fresh Medical Laboratories, Inc. ("Company"), whose address is 757 East South Temple, Suite 150 Salt Lake City, Utah 84102 When referred to collectively the Company and the Consultan |
|
| May 22, 2017 |
Amendment to Employment Agreement executed on March 29, 2017(12) EX-10.2 5 f10q033117ex10z2.htm EXHIBIT 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.2 AMENDMENT TO THE EMPLOYMENT AGREEMENT DATED EFFECTIVE AUGUST 1, 2013 THIS AMENDMENT TO THE EMPLOYMENT AGREEMENT DATED EFFECTIVE AUGUST 2, 2013 (this “Agreement”), entered into as of March 29, 2017, but effective as of August 1, 2016, (the “Effective Date”) is entered into by and between Fresh Medical Laborat |
|
| May 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 PROLUNG, INC. (FORMER |
|
| May 22, 2017 |
Form of Warrant issued in $3.2 million offering in April 2017(12) EXHIBIT 4.2 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE OFFERED, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AND SUCH REGISTRATION OR QUALIFICATION AS MAY BE NECESSAR |
|
| May 22, 2017 |
Form of Warrant issuable to Placement Agents(12) EXHIBIT 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE OFFERED, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AND SUCH REGISTRATION OR QUALIFICATION AS MAY BE NECESSAR |
|
| May 22, 2017 |
Placement Agent Agreement dated March 8, 2017 with Weild Capital, LLC(12) EXHIBIT 10.1 FRESH MEDICAL LABORATORIES, INC. PLACEMENT AGENT AGREEMENT March 6, 2017 Weild & Co., Inc. 747 Third Avenue New York, New York 10017 Attn: Mr. David Weild Gentlemen: Fresh Medical Laboratories, Inc., a Delaware corporation (the ?Company?), proposes to sell to qualified investors in a private placement shares of the Company?s common stock (the ?Shares?), at a price of $1.50 per Share. |
|
| May 16, 2017 |
NT 10-Q 1 nt10q033117nt10q.htm FORM 12B25 NOTICE OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING Commission file number: 000-54600 (Check one) . Form 10-K . Form 20-F . Form 11-K X . Form 10-Q . Form N-SAR . Form N-CSR For period ended: March 31, 2017 . Transition Report on Form 10-K . Transition Report on Form 20-F . T |
|
| May 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2017 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X . Filed by a Party other than the Registrant . Check the appropriate box: X . Preliminary Proxy Statement . Confidential, for Use of the Commission Only (as Rule 14a-6(e)(2))permitted by Rule 14a-6(e)(2)) . D |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2017 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, I |
|
| April 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) PROLUNG, INC. (FORMERLY FRES |
|
| April 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 3, 2017 ProLung, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 6, 2017 |
CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION Fresh Medical Laboratories, Inc. |
|
| April 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING Commission file number: 000-54600 (Check one) X . Form 10-K . Form 20-F . Form 11-K . Form 10-Q . Form N-SAR . Form N-CSR For period ended: December 31, 2016 . Transition Report on Form 10-K . Transition Report on Form 20-F . Transition Report on Form 11-K . Transition Report on Form 10- |
|
| February 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2017 Fresh Medical Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation o |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LAB |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LABORATO |
|
| May 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 20, 2016 Fresh Medical Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or org |
|
| May 24, 2016 |
LUNG / ProLung, Inc. / Morgan Todd M - SCHEDULE 13D FOR TODD MORGAN Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FRESH MEDICAL LABORATORIES, INC. (Name of Issuer) COMMON (Title of Class of Securities) 35804P 108 (CUSIP Number) Steven C. Eror, 757 East South Temple, Suite 150, Salt Lake City, UT 84012 (Name, Address and Telephone Number of Person Authori |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LABORAT |
|
| May 16, 2016 |
CONFIDENTIAL Subject: CONSULTING REPRESENTATION AGREEMENT This Consulting Representation Agreement (the ?Agreement?) dated January 1, 2016, is made by and between Fresh Medical Laboratories, Inc. |
|
| April 14, 2016 |
Consulting Agreement dated March 9, 2015 with Jeffrey S. O’Driscoll (9) Confidential March 19, 2015 Jeff O'Driscoll 1888 South 1800 East Salt Lake City, UT 84108 Subject: CONSULT/NG AGREEMENT LETTER This agreement ("Agreement") dated 9 March 2015 is made by and between Fresh Medical Laboratories, Inc. |
|
| April 14, 2016 |
Exhibit 21.1 List of Subsidiaries Hilltop Acquisition Corporation, Inc., a Delaware corporation (100% owned) |
|
| April 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 (Commission File No.) FRESH MEDICAL LABORATORIES, |
|
| April 14, 2016 |
Placement Agent Agreement dated December 30, 2015 with ACAP Financial Inc(9) FRESH MEDICAL LABORATORIES, INC. PLACEMENT AGENT AGREEMENT December 28, 2015 ACAP Financial, Inc. 57 West 200 South, Suite 202 Salt Lake City, Utah 84101 Attn: Mr. Kirk Ferguson Gentlemen: Fresh Medical Laboratories, Inc., a Delaware corporation (the ?Company?), proposes to sell to qualified investors in a private placement an aggregate of a maximum of 3,500,000 shares and a minimum of 333,333 sha |
|
| April 14, 2016 |
Consulting Agreement dated April 30, 2015 with Tim Treu(9) Confidential May 1, 2015 Tim Treu 931 West Northridge Road Farmington, Utah 84025 Subject: CONSULTING AGREEMENT LETTER This agreement ("Agreement") dated 30 April 2015 is made by and between Fresh Medical Laboratories, Inc. |
|
| March 31, 2016 |
NT 10-K 1 nt10k123115nt10k.htm FORM 12B25 NOTICE OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING Commission file number: 000-54600 (Check one) X . Form 10-K . Form 20-F . Form 11-K . Form 10-Q . Form N-SAR . Form N-CSR For period ended: December 31, 2015 . Transition Report on Form 10-K . Transition Report on Form 20-F |
|
| March 29, 2016 |
LUNG / ProLung, Inc. / Raybould Robert W - SCHEDULE 13D FOR RAOBERT W. RAYBOULD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) FRESH MEDICAL LABORATORIES, INC. (Name of Issuer) COMMON (Title of Class of Securities) 35804P 108 (CUSIP Number) Steven C. Eror, 757 East South Temple, Suite 150, Salt Lake City, UT 84012 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| February 23, 2016 |
BNVI / BioNovo, Inc. / EROR STEVEN C - SCHEDULE 13D FOR STEVEN C. EROR Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FRESH MEDICAL LABORATORIES, INC. (Name of Issuer) COMMON (Title of Class of Securities) 35804P 108 (CUSIP Number) Steven C. Eror, 757 East South Temple, Suite 150, Salt Lake City, UT 84012 (Name, Address and Telephone Number of Person Authori |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 .. Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LA |
|
| November 16, 2015 |
Form of Convertible Notes issued in November 2015(10) US$ Issue Date: , 2015 FRESH MEDICAL LABORATORIES, INC. CONVERTIBLE NOTE THIS CONVERTIBLE NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION OR OTHER COMPLIANCE UNDER THE 1933 ACT OR THE |
|
| August 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 20, 2015 Fresh Medical Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X . Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 . Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LABORATO |
|
| May 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-54600 FRESH MEDICAL LABORATORIE |
|
| May 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 1, 2015 Fresh Medical Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 (State or other jurisdiction of incorporation or orga |
|
| May 5, 2015 |
Amended and Restated Master Loan Agreement and Promissory Note with William Fresh(9) $900,000.00 May 1, 2015 AMENDED AND RESTATED MASTER LOAN AGREEMENT AND PROMISSORY NOTE WHEREAS, Fresh Medical Laboratories, Inc., a Delaware corporation (the ?Maker?), has entered into a series of loan agreements and promissory notes with William A. Fresh, 176 North Emeraud Drive, St. George, Utah 84770 (the ?Holder?), the most recent of which is that certain Revised Master Loan Agreement, dated M |
|
| April 28, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 23, 2015 Fresh Medical Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54600 20-1922768 State or other jurisdiction of incorporation or or |
|
| April 28, 2015 |
Exhibit 16.1 April 27, 2015 Securities and Exchange Commission 100 F Street Washington, DC 20549 Ladies and Gentlemen: On April 23, 2015, we were dismissed as the independent registered public accounting firm for Fresh Medical Laboratories, Inc. (the Company). We have read the Company?s disclosure set forth in Item 4.01, ?Changes in Registrant?s Independent Registered Public Accounting Firm? of th |
|
| March 31, 2015 |
Warrant to Purchase Common Stock Issued to William A. Fresh(8) |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 10-K 1 f10k12311410k.htm FORM 10-K ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 000-54600 ( |
|
| March 31, 2015 |
Exhibit 21.1 List of Subsidiaries Hilltop Acquisition Corporation, Inc., a Delaware corporation (100% owned) |
|
| March 31, 2015 |
Warrant to Purchase Common Stock Issued to Leavitt Partners, LLC(8) Exhibit 4.2.2 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) OR ANY APPLICABLE STATE SECURITIES LAW, AND MAY NOT BE OFFERED, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AND SUCH REGISTRATION OR QUALIFICATION AS MAY BE NECESS |
|
| March 31, 2015 |
Form of Eight Percent (8%) Convertible Debenture, dated ________, 2015(6) Exhibit 10.9 Form of Convertible Debenture US$ Debenture No. Issue Date: Maturity Date: , 2018 FRESH MEDICAL LABORATORIES, INC. EIGHT PERCENT (8%) CONVERTIBLE DEBENTURE THIS DEBENTURE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED OR SOLD IN TH |
|
| December 9, 2014 |
Second Amended and Restated Certificate of Incorporation(7) Exhibit 3.1 Second Amended and Restated Certificate of Incorporation EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FRESH MEDICAL LABORATORIES, INC. Fresh Medical Laboratories, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: 1. The original Certificate of Incorp |
